Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Rigel Pharmaceuticals (RIGL) Set to Report Q4 FY225 Earnings After the Bell — Here’s What to Expect
Rigel Pharmaceuticals (RIGL) is scheduled to report its Q4 and full-year 2025 earnings after the market closes on March 3, 2026. The company is transitioning into a profitable royalty and commercial operation, driven by growing TAVALISSE royalties. Analysts expect significant revenue and EPS growth, with key metrics to watch including full-year revenue, EPS, TAVALISSE royalty trajectory, operating expenses, and new pipeline developments to confirm the sustainability of its profitability inflection.